Our findings here identify PKM2 as a novel regulator of LPS- as well as tumor-induced PD-L1 expression on macrophages and DCs as well as tumor cells, providing new insight into the expressional control of an important target in cancer immunotherapy. The gene discussed is PKM; the disease is neoplasm.